Evidence map›Paper›PMID 33452956›Full record

ArticleInternational urology and nephrology2021

Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy.

Soichiro Yoshida, Taro Takahara, Yuki Arita, Kazuma Toda, Ichiro Yamada, Hajime Tanaka, Minato Yokoyama, Yoh Matsuoka, Ryoichi Yoshimura, Yasuhisa Fujii

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Soichiro YoshidaDepartment of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. s-yoshida.uro@tmd.ac.jp.
Taro TakaharaDepartment of Biomedical Engineering, Tokai University School of Engineering, Kanagawa, 259-1292, Japan.
Yuki AritaDepartments of Diagnostic Radiology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Kazuma TodaDepartment of Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Ichiro YamadaDepartment of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Hajime TanakaDepartment of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.
Minato YokoyamaDepartment of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.
Yoh MatsuokaDepartment of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.
Ryoichi YoshimuraDepartment of Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Yasuhisa FujiiDepartment of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.
Tokyo Medical and Dental University · JPAdvanced Imaging Research (United States) · USKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the clinical characteristics of genuine- and induced-oligometastatic castration-resistant prostate cancer (OM-CRPC) and assess the therapeutic effect of progressive-site directed therapy (PSDT).

methodsWe performed a retrospective analysis of 45 patients with OM-CRPC. Whole-body diffusion-weighted MRI (WB-DWI) was used to diagnose oligo-progressive disease. Based on the clinical and radiological findings, the OM-CRPCs were classified as genuine or induced. PSDT was performed with the intent to ablate all the progressive sites detected on WB-DWI with radiotherapy. Systemic therapy remained unchanged during and after PSDT.

resultsA total of 31 (69%) and 14 (31%) patients were diagnosed with genuine- and induced-OM-CRPC, respectively. The genuine-OM-CRPC group had significantly fewer patients treated with taxane-based chemotherapy and new hormonal drugs than the induced-OM-CRPC group. Of these, 26 OM-CRPC patients were treated with PSDT, and a 50% PSA decline was observed in 14 (93%) of 15 patients with genuine-OM-CRPC and 4 (36%) of 11 patients with induced-OM-CRPC (P = 0.033). Further, the duration of PSA-progression-free survival was significantly longer in the genuine-OM-CRPC group than in the induced-OM-CRPC group (8.7 vs. 5.8 months, P = 0.040).

conclusionsPSDT can be a promising treatment option for genuine-OM-CRPC. The procedure might also be considered effective for induced-OM-CRPC, although there was less therapeutic benefit of PSDT in patients with induced-OM-CRPC than in patients with genuine-OM-CRPC.

Indexed as

Diffusion Magnetic Resonance ImagingAgedAged, 80 and overHumansMaleNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantRadiotherapyRetrospective StudiesCastration-resistantDiffusion magnetic resonance imagingNeoplasm metastasisProstatic neoplasmsRadiotherapyWhole body imaging

Identifiers

PMID33452956
OpenAlexW3124523029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.